apixaban / Generic mfg. - LARVOL DELTA

When Liver Cancer Strikes the Kidney: A Case of Uncommon Metastasis (ACG 2025) - "The patient was started on apixaban for therapeutic anticoagulation...Systemic immune checkpoint inhibitors (tremelimumab + durvalumab) were initiated...In our case, immune checkpoint inhibitors were used instead of sorafenib due to superior survival benefits. Evidence from additional reports are needed to guide optimal treatment for renal metastasis from HCC.Figure: Histopathological findings of HCC and Kidney Mass"

Clinical • IO biomarker • Fibrosis • Gastroenterology • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Liver Cancer • Liver Cirrhosis • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor • Squamous Cell Carcinoma • Thrombosis

A Case of Acute Biliary Obstruction Due to Severe Hemorrhagic Pancreatitis and Duodenitis Due to Riluzole (ACG 2025) - "Apixaban and clopidogrel were held...She continued on dialysis and desmopressin for uremic coagulopathy...IV fluids and discontinuing the medication are the mainstay of management. Uremia and anticoagulant therapy likely contributed to the severity of the bleeding.Figure: Duodenal thickening Figure: Second portion of Duodenum"

Clinical • Amyotrophic Lateral Sclerosis • Anemia • Chronic Kidney Disease • CNS Disorders • Hematological Disorders • Nephrology • Pancreatitis • Renal Disease

Secondary Colonic Plasmacytoma Presenting as a Rare Cause of Intussusception (ACG 2025) - "We describe a case of secondary colonic EMP presenting clinically with hematochezia and intussusception.Case Description/ A 59-year-old male with a new diagnosis of MM, recently initiated on induction chemotherapy and apixaban, presented with a single episode of gelatinous hematochezia...The patient subsequently received one fraction of radiation to the mass, followed by alternative induction chemotherapy regimen including Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone. Secondary colonic EMP is a rare manifestation and sequela of MM, often indicating aggressive disease and a poor prognosis...CT of the Abdomen Demonstrating Ileocolonic IntussusceptionFigure: Figure 2. Colonoscopy Demonstrating an Obstructing Mass in the Ascending Colon"

Gastrointestinal Disorder • Hematological Malignancies • Multiple Myeloma • Pediatrics • Plasmacytoma • NCAM1 • PAX5 • SDC1 • SYP

Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance (Businesswire) - "Second-quarter 2025 revenues totaled $14.7 billion, an increase of $1.4 billion, or 10%, compared to the prior-year quarter, reflecting an operational increase of $1.3 billion, or 10%, as well as a favorable impact of foreign exchange of $22 million. The operational increase was primarily driven by an increase in revenues for the Vyndaqel family, Comirnaty, Paxlovid, Padcev, Eliquis and several other products across categories despite the unfavorable impact of higher manufacturer discounts resulting from the Inflation Reduction Act (IRA) Medicare Part D Redesign."

Commercial • Cardiovascular • CNS Disorders • Novel Coronavirus Disease • Urothelial Cancer

Beyond the Adenoma: A Rare Case of Colonic Melanoma Metastasis (ACG 2025) - "We report a case of metastatic melanoma found incidentally within colonic polyps during evaluation for symptomatic anemia.Case Description/ A 76-year-old male with metastatic melanoma (lungs, brain, left ear) was receiving Opdualag and Mektovi. His history included non-small cell lung cancer, atrial fibrillation on apixaban, CAD, and stage III CKD...First line systemic therapy includes anti–PD–1 agents (e.g. nivolumab, pembrolizumab), alone or with anti–CTLA–4. BRAF V600E/K-mutated tumors may respond to BRAF/MEK inhibitors. In conclusion, awareness of this rare entity is key to accurate diagnosis and timely oncologic management.Figure: High-power (40X) H&E-stained section of ascending colon shows malignant melanoma cells with abundant melanin pigment (circled) and prominent "cherry-red" nucleoli (arrows).Figure: Melan-A immunohistochemical stain of the ascending colon, highlighting malignant melanoma cells in brown."

Clinical • IO biomarker • Anemia • Atrial Fibrillation • Chronic Kidney Disease • Colon Cancer • Colonic Polyps • Colorectal Cancer • Fatigue • Gastroenterology • Gastrointestinal Disorder • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Pulmonary Disease • Solid Tumor • MLANA • SOX10

HI-PRO: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (ESC-WCC 2025) - No abstract available

Cardiovascular • Venous Thromboembolism

Low-dose edoxaban in patients 80 years and older with atrial fibrillation and dose-reduction criteria: randomized analysis between edoxaban 15 mg and 30 mg (ESC-WCC 2025) - "Overall, 3591 patients (17%) were ≥80 years; the 80-year cutoff for this analysis was based on the dose-reduction criteria for apixaban and previous studies. Compared with warfarin, major bleeding events were significantly lower with edoxaban 15 mg (HR 0.34, 95% CI 0.21–0.53) and edoxaban 30 mg (HR 0.66, 95% CI 0.45–0.95). CONCLUSION In a randomized comparison of AF patients ≥80 years meeting dose-reduction criteria, once daily edoxaban 15 mg resulted in comparable rates of stroke or systemic embolism relative to 30 mg, with significantly fewer major and intracranial bleeding events and a trend toward more ischemic strokes."

Clinical • Atrial Fibrillation • Cardiovascular • Ischemic stroke

Apixaban vs. warfarin for venous thromboembolism in renal impairment: a meta-analysis of efficacy and safety (ESC-WCC 2025) - "Apixaban may be more effective and safer than warfarin for VTE treatment in CKD patients. Further RCTs are needed to confirm these findings."

Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure • Venous Thromboembolism

Clinical impact of kidney function in patients with atrial fibrillation receiving oral anticoagulants (ESC-WCC 2025) - "Lower Ccr was significantly associated with a higher thrombotic risk in patients receiving dabigatran (p=0.026), rivaroxaban (p=0.001), and warfarin (p=0.010), while a higher bleeding risk was observed in those receiving edoxaban (p<0.001) and warfarin (p=0.023). However, among those receiving apixaban, renal function did not significantly influence the incidence of either outcome. These results provide valuable insights for optimizing anticoagulation therapy based on individual patient characteristics."

Clinical • Atrial Fibrillation • Cardiovascular • Thrombosis

Direct oral anticoagulants versus low-molecular-weight heparin for thromboprophylaxis in cancer-related surgeries: a meta-analysis of efficacy and safety outcomes (ESC-WCC 2025) - "This meta-analysis indicates that DOACs are non-inferior to LMWH for post-operative thromboprophylaxis in patients undergoing cancer-related surgeries, with comparable safety profiles. The superior efficacy of DOACs in preventing VTE during urological cancer surgeries and the favorable safety profile of Apixaban warrant further investigation. Given the changing landscape of anticoagulation strategies in cancer care, additional research is essential to clearly define the roles of specific DOAC agents and optimal prophylactic approaches across various cancer types and surgical procedures."

Retrospective data • Surgery • Cardiovascular • Venous Thromboembolism

Thrombocheck: a drug-drug interactions guide for cardiologists prescribing antithrombotic therapy (ESC-WCC 2025) - " First, a clinical pharmacist and a physician independently analysed the literature on DDI for 8 AT: 5 OAC (rivaroxaban, apixaban, edoxaban, dabigatran and acenocoumarol) and 3 AA (clopidogrel, ticagrelor and prasugrel). Aspirin was excluded as it is not known for PK DDI... Antithrombotic therapies are susceptible to numerous DDI. This simple yet important tool can help cardiologists minimize significant DDI when prescribing new AT, guiding them toward safer et more effective treatment options."

Cardiovascular

Changes in anticoagulation treatment and associated resolution or persistence of left atrial thrombus. Insights from LATTEE registry (ESC-WCC 2025) - "Conclusions. Based on our results, following anticoagulation scheme changes may be recommended for LAT resolution: start VKA for anticoagulant-naïve patients, switch VKA to dabigatran, continue dabigatran or rivaroxaban, and change apixaban to another NOAC."

Atrial Fibrillation • Cardiovascular • Thrombosis

The key determinants of oral anticoagulant treatment experience in atrial fibrillation patients (ESC-WCC 2025) - "NOACs were used by 53% of patients, mainly rivaroxaban (38%), apixaban (11%), and edoxaban (4%), while 47% used VKAs, primarily warfarin (25%) and acenocoumarol (22%). The study highlights that socioeconomic factors, particularly education level and household income, play a crucial role in the perceived convenience and satisfaction with OAC therapy in AF patients. Patients receiving VKA therapy reported lower treatment convenience, possibly due to the need for frequent monitoring and dietary restrictions.These findings underscore the importance of individualized patient support and education to optimize adherence and overall treatment experience in anticoagulated AF patients."

Clinical • Atrial Fibrillation • Cardiovascular • Dyslipidemia

Impact of real-world off-label dose of apixaban on long-term clinical outcomes in heart failure patients with atrial fibrillation and end stage kidney disease (ESC-WCC 2025) - "There was no significant difference of systemic thrombotic events including stroke/systemic embolism and death with no difference in the risk of bleeding in HF patients with AF and ESKD, supporting the apixaban dosing tailored to specific clinical features and drug pharmacokinetics of the Asian patients."

Clinical • Clinical data • Real-world • Real-world evidence • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure

Cost-effectiveness of apixaban vs aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from the ARTESiA trial (ESC-WCC 2025) - "In patients with device detected atrial fibrillation with CHA₂DS₂-VASc score >4, apixaban is cost-saving in Canada and the UK and cost-effective in Germany. Apixaban is not cost-effective in the US at current prices."

Clinical • Cost effectiveness • HEOR • Atrial Fibrillation • Cardiovascular • Ischemic stroke • Myocardial Infarction

Anti-infective potentials of dabigatran and direct oral anticoagulants in patients with cardiac implantable electronic devices (ESC-WCC 2025) - "DOACs, particularly dabigatran and apixaban, may reduce the risk of sepsis compared to warfarin in CIED patients who have an indication for long-term anticoagulation."

Clinical • Cardiovascular

Self-adaptive covalent coating for vascular stents: coordinated coagulation-inflammation regulation to support re-endothelialization for atherosclerosis control (ESC-WCC 2025) - "Here, we designed a self-adaptive covalent coating stent that integrates thrombin-responsive release of the anticoagulant apixaban as a coagulation modulator and the antioxidant polyphenol as an anti-inflammatory...Furthermore, the coated stent implantation in a atherosclerotic rabbit model demonstrated that the coating inhibites plaque deterioration, associated with inflammation and endothelial damage. This dual-responsive strategy offers a promising avenue for therapeutic stents by mitigating the coagulation-inflammation loop and supporting endothelial repair in atherosclerotic vessels."

Atherosclerosis • Cardiovascular

A novel heart valve design reduces turbulence in aortic flow (ESC-WCC 2025) - "However, the bleeding risk persists and the recent PROACT Xa trial failed to show the noninferiority of apixaban to warfarin in patients with an On-X valve [2]. The vortical structures distal to the FMV during systole were less coherent compared to the On-X valve, as demonstrated by the shorter and smaller vortex tubes in figure 2 (A, C). During diastole, significantly fewer vortices were present in the downstream flow of the FMV (figure 2 B, D), indicating a faster decay of turbulence. This was equivalent to a total of 23% reduction in turbulent kinetic energy, highlighting the effectiveness of our design methodology."

Cardiovascular

Effectiveness and safety of rivaroxaban vs apixaban in patients with Atrial Fibrillation and Peripheral Artery Disease (ESC-WCC 2025) - "In patients with NVAF and PAD, rivaroxaban and apixaban showed similar effectiveness for preventing MALE and stroke/TIA/SE. However, rivaroxaban was associated with a higher risk of major bleeding. These findings support apixaban as a potentially safer anticoagulant in this high-risk population."

Clinical • Atrial Fibrillation • Cardiovascular • Ischemic stroke • Myocardial Infarction • Peripheral Arterial Disease

Use of direct oral anticoagulants in patients with atrial fibrillation and cancer: a subanalysis of the nationwide Italian START registry (ESC-WCC 2025) - "At univariable Cox regression analysis, we found that Apixaban (HR: 0.535, 95% CI: 0.421–0.679, p < 0.001), Rivaroxaban (HR: 0.564, 95% CI: 0.436–0.729, p < 0.001), Edoxaban (HR: 0.502, 95% CI: 0.346–0.730, p < 0.001), and Dabigatran (HR: 0.421, 95% CI: 0.315–0.562, p < 0.001) were associated with a lower all-cause mortality risk compared to warfarin. In conclusions, DOACs seem to be associated with a lower mortality and CVEs compared to VKAs in patients with AF and cancer, independently from the DOAC prescribed. DOACs may represent an optimal choice in AF patients with cancer."

Clinical • Atrial Fibrillation • Cardiovascular

Anticoagulation strategy of choice for atrial fibrillation ablation - a network meta-analysis of complication rates (ESC-WCC 2025) - "Small studies have suggested some differences in efficacy for interrupted and uninterrupted regimens, as well as individual DOACs (dabigatran (D), apixaban (A), rivaroxaban (R), edoxaban (E). This meta-analysis shows that safety is similar among D, A, R, E, either interrupted or uninterrupted strategy. iD has a significantly lower complication rate than uVKA offering a safer profile. Our data supports the use of DOACs or uVKA as anticoagulation regimens peri AF ablation."

Retrospective data • Atrial Fibrillation • Cardiovascular

Efficacy and safety of direct oral anticoagulants in patients with device-detected atrial fibrillation with and without dose reduction criteria: a pooled analysis of ARTESiA and NOAH-AFNET 6 (ESC-WCC 2025) - "On behalf: ARTESiA and NOAH-AFNET 6 Investigators BackgroundIn patients with device-detected atrial fibrillation (AF), direct oral anticoagulants (DOACs), as compared to aspirin or placebo, reduce thrombotic events and increase major bleeding...Results Among 4,012 patients in ARTESiA, 10.4% met apixaban dose reduction criteria...There was for a possible greater absolute benefit for edoxaban against the stroke, systemic embolism, myocardial infarction, pulmonary embolism or cardiovascular death outcome in the reduced dose strata in the NOAH-AFNET 6 trial. This requires further study using patient-level data."

Retrospective data • Atrial Fibrillation • Cardiovascular • Myocardial Infarction • Pulmonary Embolism

The first year of generic NOACs: implications for patients and the healthcare system (ESC-WCC 2025) - "Among NOACs – branded and generic - sold during the study period, apixaban accounted for 53.2%, rivaroxaban 23.5%, edoxaban 13.2% and dabigatran 10.2%. CONCLUSION Generic have been widely adopted by patients in Portugal leading to a significant decrease in costs for patients and the public healthcare system. Economic factors and previous experience with generic drugs likely influenced patient choice."

Clinical • Atrial Fibrillation • Cardiovascular

Ticagrelor versus clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention and using direct oral anticoagulants (ESC-WCC 2025) - "Additionally, patients were censored when they filled a prescription for another P2Y12 inhibitor or for aspirin. Results In total, 3,708 patients were included (median age: 76 years; 69% male; 12% smokers; 14% diabetes; 40% ST-elevation myocardial infarction; DOAC: 70% apixaban, 19% rivaroxaban, 9% dabigatran, 2% edoxaban) (Table 1)...For stroke and stent thrombosis, the rates were 1.4% versus 1.2% and 0.3% versus 0.4%, respectively, and no significant differences were found. Conclusion In ACS patients on DOACs undergoing PCI, ticagrelor was associated with a higher bleeding risk compared to clopidogrel, with no differences in MACE, mortality, or reinfarction."

Clinical • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction • Thrombosis

Rare Case of Primary Gastric Diffuse Large B Cell Lymphoma Status Post Helicobacter pylori: Treatment and Clearance (ACG 2025) - "Diffuse large B-cell lymphoma (DLBCL) is the most common histologic subtype of primary gastric lymphoma; however, the germinal center B-cell (GCB) phenotype is less frequently found in the stomach (one-third of cases) compared to the activated B-cell (ABC) phenotype.1,2Case Description/ A 75-year-old male with atrial fibrillation on Eliquis and chronic iron deficiency anemia was admitted to the hospital for abdominal pain, coffee ground emesis, and melena...His oncology team is planning for 3 cycles of R-CHOP followed by radiation. Diffuse large B-cell lymphoma (DLBCL), germinal center B-cell (GCB) type, stage IE of the stomach is rare...Gastric malignancy of any kind was low on the differential diagnosis considering he had a relatively unremarkable EGD less than 2 years prior and his H. pylori infection had been successfully treated. This is a rare case of gastric DLBCL development despite successful H. pylori treatment.Figure: ulcerated mass in gastric body extending..."

Clinical • Anemia • Atrial Fibrillation • B Cell Lymphoma • Cardiovascular • Diffuse Large B Cell Lymphoma • Gastric Cancer • Hematological Malignancies • High-grade B-cell lymphoma • Immunology • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • BCL2